Finland’s Forendo Pharma Ltd. is to collaborate with Novartis AG on identifying novel drug candidates for the treatment of chronic liver diseases, in what appears to be the first big pharma deal for the northern European clinical-stage drug development company.
Finland's Forendo Attracts Big Pharma For Liver Disease R&D
Deal To Boost Novartis's Liver Disease Efforts
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.